Drug products: Betametason Trimb, Betametason-neomycin i Essex kräm APL, Betnovat, Betnovat®, Betnovate, Bettamousse, Calcipotriol/Betamethasone Sandoz, Calcipotriol/Betamethasone Teva, Celeston® valerat, Daivobet, Daivobet®, Diproderm®, Diprolen®, Diprotit, Dovobet, Dovobet®, Enstilar, Enstilar®, Fusidinsyra/Betametason Ebb, Fusidinsyra/Betametason LEO, Kalcipotriol/Betametason Ebb, Xamiol, Xamiol®
ATC code: D05AX52, D07AC01, D07CC01, S02BA07
Published controlled studies on sex differences in effect and safety of topical betamethasone are lacking.
Topical betamethasone is used for treatment of corticosteroid-responsive dermatoses . Topical corticosteroids may be systematically absorbed if used on large areas, on broken skin, or under occlusive dressings . No difference between men and women has been shown for transdermal absorption in general .
No studies on sex differences in pharmacokinetics or dosing for topical betamethasone have been found.
No studies with a clinically relevant sex analysis regarding the effects of topical betamethasone have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of topical betamethasone have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men .
Date of litterature search: 2017-01-02
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson